Related Experiment Video
Updated: Jul 23, 2025
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
956
Tirofiban-induced thrombocytopenia.
1Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Annals of Medicine
|July 13, 2023
Summary
Tirofiban, a Glycoprotein IIb/IIIa inhibitor, prevents platelet aggregation in acute coronary syndrome. However, it can cause immune-mediated thrombocytopenia, a concerning side effect requiring careful management and risk factor assessment.
Area of Science:
- Cardiovascular pharmacology
- Hematology
Background:
- Tirofiban is a Glycoprotein (GP) IIb/IIIa inhibitor used to prevent thrombotic events in non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
- While effective, tirofiban has been linked to thrombocytopenia, a significant adverse reaction.
Purpose of the Study:
- To review the pathophysiology, clinical presentation, management, and risk factors of tirofiban-induced thrombocytopenia.
- To raise awareness of this adverse effect given tirofiban's common use in cardiovascular care.
Main Methods:
- Literature review of case reports and clinical trials concerning tirofiban and thrombocytopenia.
- Analysis of proposed immune-mediated mechanisms.
Main Results:
- Tirofiban-induced thrombocytopenia is an immune-mediated adverse reaction.
- Understanding its pathogenesis, presentation, and risk factors is crucial for patient safety.
Conclusions:
- Tirofiban-induced thrombocytopenia is a serious concern in NSTE-ACS patients.
- Further research into its mechanisms and improved management strategies are warranted.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
566
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
566
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
763
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
763
01:16Clot Retraction and Fibrinolysis
6.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.5K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:17Intracellular Signaling Affects Focal Adhesions
2.7K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.7K